These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38976671)

  • 1. Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients.
    Ma MC; Lavi ES; Altwerger G; Lin ZP; Ratner ES
    PLoS One; 2024; 19(7):e0305273. PubMed ID: 38976671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
    Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
    Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M
    J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2.
    Eoh KJ; Kim JE; Park HS; Lee ST; Park JS; Han JW; Lee JY; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ
    Cancer Res Treat; 2018 Jul; 50(3):917-925. PubMed ID: 29020732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
    Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
    Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
    Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the Homologous Recombination Repair Mutation Defined by a 15-Gene Panel Associated with the Prognosis of Epithelial Ovarian Cancer?
    Liu Y; Chen X; Lu H; Wu X; Liu X; Xu F; Ye D; Ding B; Lu X; Qiu L; Zhu J; Wang Y; Huang X; Shen Z; Zhu T; Shen Y; Zhou Y
    Mol Diagn Ther; 2024 Sep; 28(5):621-632. PubMed ID: 38967864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
    Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
    Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
    Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.
    Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF
    Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
    Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
    Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
    Nodin B; Zendehrokh N; Sundström M; Jirström K
    Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
    Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
    World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.
    Hu JL; Hu XL; Han Q; Guo AY; Wang CJ; Wen YY; Cang SD
    Gene Ther; 2017 Jul; 24(7):392-398. PubMed ID: 28436941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    Wysham WZ; Mhawech-Fauceglia P; Li H; Hays L; Syriac S; Skrepnik T; Wright J; Pande N; Hoatlin M; Pejovic T
    PLoS One; 2012; 7(1):e30042. PubMed ID: 22253870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.